Real-World Data on Newly Diagnosed -Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database.

Background: In spite of the frequency and clinical impact of alterations in high-grade epithelial ovarian cancer (HGEOC), real-world information based on robust data warehouse has been scarce to date.

Methods: Consecutive patients with -mutated HGEOC treated between 2011 and 2016 within French comprehensive cancer centers from the Unicancer network were extracted from the ESME database. The main objective of the study was the assessment of clinicopathological and treatments parameters.

Results: Out of the 8021 patients included in the ESME database, 266 patients matching the selection criteria were included. mutation was found in 191 (71.8%) patients, while 75 (28.2%) had a mutation only; 95.5% of patients received a cytoreductive surgery. All patients received a taxane/platinum-based chemotherapy (median = six cycles). Complete and partial response were obtained in 53.3% and 20.4% of the cases, respectively. Maintenance therapy was administered in 55.3% of the cases, bevacizumab being the most common agent. After a median follow up of 51.7 months, a median progression-free survival of 28.6 months (95% confidence interval (CI) [26.5; 32.7]) and an estimated 5-year median overall survival of 69.2% (95% CI [61.6; 70.3]) were reported. Notably, - and -mutated cases exhibited a trend towards different median progression-free survivals, with 28.0 (95% CI [24.4; 32.3]) and 33.3 months (95% CI [26.7; 46.1]), respectively (-value = 0.053). Furthermore, five-year OS for -mutated patients was 64.5% (95% CI [59.7; 69.2]), while it was 82.5% (95% CI [76.6; 88.5]) for -mutated ones (-value = 0.029).

Conclusions: This study reports the largest French multicenter cohort of -mutated HGEOCs based on robust data from the ESME, exhibiting relevant real-world data regarding this specific population.